Placebo News and Research

RSS

Study elucidates potential benefits of antiarrhythmic drugs for out-of-hospital cardiac arrest patients

Paramedics often give heart rhythm stabilizing drugs to patients who are suffering out-of-hospital cardiac arrest when they fail to regain a stable heart rhythm after electrical shock treatment.

5 Apr 2016

New stem cell therapy significantly improves outcomes in patients with severe heart failure

A new stem cell therapy significantly improved long-term health outcomes in patients with severe and end-stage heart failure in a study presented at the American College of Cardiology's 65th Annual Scientific Session.

5 Apr 2016

Investigational drug provides no improved protection to patients with contrast-induced acute kidney injury

Patients treated with CMX-2043--an investigational drug that has previously shown some ability to protect heart muscle from damage during stenting--saw no improved protection in their kidneys compared to placebo, according to research presented at the American College of Cardiology's 65th Annual Scientific Session.

5 Apr 2016

New implantable medical device fails to reduce rates of heart failure-related hospitalization

A new implantable medical device intended to help patients with heart failure by stimulating the vagus nerve did not significantly reduce rates of heart failure-related hospitalization or death from any cause in a study presented at the American College of Cardiology's 65th Annual Scientific Session.

5 Apr 2016

Adding liraglutide to diet and exercise plan may help people lose weight, reduce diabetes risk

For people with prediabetes who are overweight or obese, adding 3.0 mg of liraglutide for three years to a diet and exercise plan may lead to major health improvements, new industry-sponsored research suggests. The results will be presented Monday, April 4, at ENDO 2016, the annual meeting of the Endocrine Society, in Boston.

5 Apr 2016

Investigational stem cell therapy improves outcomes in patients with severe heart failure

An investigational stem cell therapy derived from patients' own blood marrow significantly improved outcomes in patients with severe heart failure, according to a study from the Cedars-Sinai Heart Institute.

5 Apr 2016

End-stage heart failure patients treated with cell therapy experience fewer cardiac events

End-stage heart failure patients treated with stem cells harvested from their own bone marrow experienced 37 percent fewer cardiac events - including deaths and heart failure hospital admissions - than a placebo-controlled group, according to a new study.

5 Apr 2016

Evolocumab could be more effective than ezetimibe in lowering cholesterol in statin-intolerant patients

In the first major trial of its kind, Cleveland Clinic researchers used a blinded rechallenge with atorvastatin or placebo to objectively confirm the presence of muscle-related symptoms in patients with a history of intolerance to multiple statins and found that evolocumab (a PCSK9 inhibitor) was a more effective option to lower cholesterol than ezetimibe in these patients.

4 Apr 2016

Intravenous beta blockers offer no clinical benefit to patients with STEMI

Giving intravenous beta blockers before performing a coronary angioplasty in patients who had experienced the deadliest form of heart attack—ST-segment elevation myocardial infarction (STEMI)—was safe but did not reduce heart attack severity or improve blood flow from the heart's main pumping chamber, according to research presented at the American College of Cardiology's 65th Annual Scientific Session.

4 Apr 2016

Researchers compare lipid-lowering efficacy for two nonstatin therapies in statin-intolerant patients

Steven E. Nissen, M.D., of the Cleveland Clinic, and colleagues identified patients with muscle-related adverse effects from statins and compared lipid-lowering efficacy for two nonstatin therapies, ezetimibe and evolocumab. The study was published online by JAMA, and is being released to coincide with its presentation at the American College of Cardiology's 65th Annual Scientific Session & Expo.

4 Apr 2016

Investigational drug abaloparatide-SC may help increase bone mineral density in postmenopausal women

The investigational drug abaloparatide-SC (subcutaneous) may help increase bone mineral density in postmenopausal women and reduce their risk of fracture, new industry-sponsored research suggests. The results of the subgroup analysis within the ACTIVE clinical trial will be presented Friday, April 1, at ENDO 2016, the annual meeting of the Endocrine Society in Boston.

4 Apr 2016

Cholesterol drug evacetrapib fails to reduce risk of cardiovascular events

Despite lowering low-density lipoprotein (LDL), known as "bad" cholesterol, while markedly increasing levels of high-density lipoprotein (HDL), or "good" cholesterol, a large clinical trial to investigate the cholesterol drug evacetrapib was discontinued early after a preliminary analysis showed it did not reduce rates of major adverse cardiovascular events, according to research presented at the American College of Cardiology's 65th Annual Scientific Session.

4 Apr 2016

Janssen announces CHMP positive opinion for use of paliperidone palmitate 3-monthly injection for schizophrenia treatment

Janssen UK announced today that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the use of paliperidone palmitate 3-monthly injection for the maintenance treatment of schizophrenia in the European Union.

4 Apr 2016

Baricitinib drug shows significant success in treatment of rheumatoid arthritis

In a clinical phase-3-study, an international research cooperation of MedUni Vienna and Stanford University has achieved significant success with the drug Baricitinib for the treatment of rheumatoid arthritis. The test persons exhibited significantly less symptoms of the disorder. The results are now published in the top scientific journal "New England Journal of Medicine".

31 Mar 2016

Researchers aim to improve reliability of future obesity research

Exposing common statistical errors and bias in obesity research to improve the reliability of future research is the aim of the authors of three new papers and a commentary published today in the April issue of Obesity, the scientific journal of The Obesity Society.

30 Mar 2016

FDA proposes to change regulation of ECT treatment

For decades, people with severe depression, bipolar disorder, and other major mental health conditions have gotten help from the treatment known as ECT, when nothing else helped them.

24 Mar 2016

Anticonvulsant medication gabapentin effectively reduces common complication of PONV

The anticonvulsant medication gabapentin—already a useful part of strategies to control pain after surgery—also effectively reduces the common complication of postoperative nausea and vomiting (PONV), reports a study in Anesthesia & Analgesia.

23 Mar 2016

Cinqair (reslizumab) approved for treatment of severe asthma

The U.S. Food and Drug Administration today approved Cinqair (reslizumab) for use with other asthma medicines for the maintenance treatment of severe asthma in patients aged 18 years and older. Cinqair is approved for patients who have a history of severe asthma attacks (exacerbations) despite receiving their current asthma medicines.

23 Mar 2016

Antipsychotic medications may not be effective in preventing delirium in hospitalized patients

A recent review of the medical literature does not support the use of antipsychotic medications for preventing or treating delirium in hospitalized patients.

23 Mar 2016

Anthim (obiltoxaximab) injection approved for treatment of inhalational anthrax

On Friday, March 18, the U.S. Food and Drug Administration approved Anthim (obiltoxaximab) injection to treat inhalational anthrax in combination with appropriate antibacterial drugs. Anthim is also approved to prevent inhalational anthrax when alternative therapies are not available or not appropriate.

21 Mar 2016

Placebo News and Research

Study elucidates potential benefits of antiarrhythmic drugs for out-of-hospital cardiac arrest patients

New stem cell therapy significantly improves outcomes in patients with severe heart failure

Investigational drug provides no improved protection to patients with contrast-induced acute kidney injury

New implantable medical device fails to reduce rates of heart failure-related hospitalization

Adding liraglutide to diet and exercise plan may help people lose weight, reduce diabetes risk

Investigational stem cell therapy improves outcomes in patients with severe heart failure

End-stage heart failure patients treated with cell therapy experience fewer cardiac events

Evolocumab could be more effective than ezetimibe in lowering cholesterol in statin-intolerant patients

Intravenous beta blockers offer no clinical benefit to patients with STEMI

Researchers compare lipid-lowering efficacy for two nonstatin therapies in statin-intolerant patients

Investigational drug abaloparatide-SC may help increase bone mineral density in postmenopausal women

Cholesterol drug evacetrapib fails to reduce risk of cardiovascular events

Janssen announces CHMP positive opinion for use of paliperidone palmitate 3-monthly injection for schizophrenia treatment

Baricitinib drug shows significant success in treatment of rheumatoid arthritis

Researchers aim to improve reliability of future obesity research

FDA proposes to change regulation of ECT treatment

Anticonvulsant medication gabapentin effectively reduces common complication of PONV

Cinqair (reslizumab) approved for treatment of severe asthma

Antipsychotic medications may not be effective in preventing delirium in hospitalized patients

Anthim (obiltoxaximab) injection approved for treatment of inhalational anthrax

Exploring the G:Box and for high-quality imaging

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Latest News